It’s a new year and we are back with an exciting next event featuring our partner Bridge Biotherapeutics! Join us on Thursday, February 9th.
Bridge Biotherapeutics is a publicly traded, clinical-stage South Korean biopharma company with a global footprint – it has operations in the US and a dedicated partnership with BaseLaunch to access external innovation in Europe. The company was founded in 2015 with a dual business model of sourcing and accessing early external innovation complemented by in-house discovery and development of novel therapeutics.
Bridge Biotherapeutics focuses on therapeutic areas with high unmet needs like ulcerative colitis, fibrotic diseases, and cancer. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations. All three programs are currently in clinical studies, along with several preclinical programs.
With their partnership with BaseLaunch, Bridge Biotherapeutics is looking for European partnerships and investment opportunities in their disease areas of interest and – more broadly – novel discovery platform technologies.
Join us to hear more about Bridge Bio’s history, IPO, their programs and discover how to connect, engage and become their partner!
* A Map of the location will be shared in the confirmation e-mail.